The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
The company has received five final approvals
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
Recommendation is based on pivotal data from the phase III POLARIX study
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Subscribe To Our Newsletter & Stay Updated
